Impact of drug policy on the use of parenteral cephalosporins in Italy

Pharmacy World and Science

Volumn 24, Issue 5, 2002, Pages 169-171

  Damiani, Gianfranco ^a   Federico, Bruno ^a   Oradei, Marco ^a   Vanini, Gian Carlo ^a   Bellocco, Rino ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Defined daily dose; Drug policy; Drug use; Intramuscularly administered cephalosporins; Italy

Indexed keywords

CEFALOTIN; CEFAMANDOLE; CEFAZOLIN; CEFEPIME; CEFODIZIME; CEFONICID; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG COST; DRUG USE; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; ITALY; PRACTICE GUIDELINE; PRESCRIPTION;

CEPHALOSPORINS; DRUG AND NARCOTIC CONTROL; HUMANS; INJECTIONS, INTRAMUSCULAR; ITALY; PRESCRIPTIONS, DRUG;

EID: 0036797410     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020523014915     Document Type: Article

References (10)

1. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-3.
2. Osservatorio Nazionale sull'Impiego dei Medicinali. L'uso dei Farmaci in Italia - 1°Rapporto Nazionale - I Semestre 2000. Rome: Ministero della Sanità, Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza, 2001
3. Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza. Elenco delle "note" aggiornate e revisionate dalla Commissione Unica del Farmaco. Bollettino d'Informazione sui Farmaci 1998;2:20-1.
4. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. Oslo: WHO; 2000.
5. http://www.istat.it (8 August 2001).
6. L'Informatore Farmaceutico. Milano: OEMF, 2000.
7. Gill PS, Freemantle N, Bero L, Haaijer-Ruskamp F, Markela M, Barjesteh KP. GP's prescribing behaviour may be affected by drug promotion. BMJ 1996;313:367.
8. World Health Organization. World Health Organization Report on Infectious Diseases 2000. Overcoming Antimicrobial Resistance http://www.who.int/infectious-disease-report/2000/index.html. (6 August 2001)
9. Seppala H, Klaukka T, Vuopio-Varkil J, Muotiala A, Helenius H, Lager K et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337(7):441-6.
10. Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza. Le nuove note CUF. Bollettino D'informazione sui Farmaci 2000;5-6(Sept-Dec):20-1.